Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

December 01, 2011 (Vol. 31, No. 21)

Gene Therapy Briefs

  • Advanced Cell Technology (ACT) said its ability to carry out the first human embryonic stem cell (hESC) trial in Europe won’t be affected by the Court of Justice of the European Union’s decision that stem cell research based on the destruction of human embryos cannot be patented (see ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.